- Shadow Work: How Businesses Are Turning Us All Into Unpaid Laborers
- IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price
- Boomers' Biggest Retirement Regret? They Didn't Work Longer
- Carnival CEO Aims to Bust the Biggest Myths About the Cruise Industry
- The 10 Poorest States in America
Alexza expects US and European regulators to announce approval decisions in December.
Traders are already bidding up shares of Celsion in anticipation of pivotal trial results.
Supernus share should fall now that 10 million shares under lock-up can now be sold.
Traders need to be less cocky and more prepared for when stocks fall.
The biotech bull market has created a new category of swing trade catalysts.
Biotech swing trader Mark Messier warns to look at Hemispherx as a short-term trade, not an investment.
Get in Zogenix early before other traders start speculating over its chronic pain drug Zohydro.
Biotech trader Mark Messier explains how to position trades ahead of two important biotech clinical trials.
Biotech trader Mark Messier explains how to swing trade Dynavax into a Nov. 14 FDA advisory panel.